Nimotuzumab combined with radiation therapy in the treatment of infiltrating and diffuse brain stem tumors in children and adolescents
Keywords:
radiotherapy, nimotuzumab, brain stem tumors, survival, children, adolescents.Abstract
Introduction: Infiltrating and diffuse gliomas of the brain stem in children and adolescents lead to a poor prognosis and a short survival time.
Objective: Present the results obtained with the combination of nimotuzumab and radiotherapy in brain stem tumors in children and adolescents.
Methods: The monoclonal antibody called nimotuzumab combined with radiotherapy was applied in a series of 69 patients aged between 2 and 18 years, from 2008 to 2020, and followed until August 2021. They were irradiated at the National Institute of Oncology and Radiobiology in Havana, with a dose in a range of 54 to 59 Gy. Nimotuzumab was applied at the dose of 150 mg/m2 of body surface area, once a week while the radiation treatment was active, then every 2 weeks with the same dose, and finally once a month for 1, 2 or more years.
Results: At the end of the combined treatment of radiotherapy and nimotuzumab, there was a response in 89.9 % of the patients. The median overall survival time was 18.8 months and series survival rates were 76.4; 45,4; 38,9; 32,8; and 31.5% at one, two, three, four, five and more years, respectively, and it was stabilized from this time to 10 years and more. Three relapsed patients were re-radiated.
Conclusions: The combination of radiotherapy and nimotuzumab was well tolerated and is an option for the treatment in brain stem tumors in children and adolescents.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Avisos de derechos de autor propuestos por Creative Commons
1. Política propuesta para revistas que ofrecen acceso abierto
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
